Quest Diagnostics Incorporated (NYSE:DGX) Position Lessened by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale trimmed its position in shares of Quest Diagnostics Incorporated (NYSE:DGXGet Rating) by 1.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 540,069 shares of the medical research company’s stock after selling 9,650 shares during the period. DekaBank Deutsche Girozentrale owned about 0.44% of Quest Diagnostics worth $91,960,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Lindbrook Capital LLC raised its holdings in Quest Diagnostics by 62.3% during the fourth quarter. Lindbrook Capital LLC now owns 245 shares of the medical research company’s stock valued at $42,000 after buying an additional 94 shares in the last quarter. Glassman Wealth Services raised its holdings in Quest Diagnostics by 57.1% during the third quarter. Glassman Wealth Services now owns 297 shares of the medical research company’s stock valued at $43,000 after buying an additional 108 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Quest Diagnostics by 762.9% during the third quarter. Jones Financial Companies Lllp now owns 302 shares of the medical research company’s stock valued at $44,000 after buying an additional 267 shares in the last quarter. Cordasco Financial Network bought a new position in Quest Diagnostics during the third quarter valued at about $48,000. Finally, Wolff Wiese Magana LLC raised its holdings in Quest Diagnostics by 62.1% during the fourth quarter. Wolff Wiese Magana LLC now owns 287 shares of the medical research company’s stock valued at $50,000 after buying an additional 110 shares in the last quarter. Institutional investors and hedge funds own 86.45% of the company’s stock.

DGX has been the topic of several recent research reports. KeyCorp raised their target price on Quest Diagnostics from $168.00 to $170.00 and gave the company an “overweight” rating in a report on Monday, December 13th. Morgan Stanley dropped their price objective on Quest Diagnostics from $159.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Monday, February 14th. Jefferies Financial Group lowered Quest Diagnostics from a “buy” rating to a “hold” rating and set a $135.00 price objective on the stock. in a research note on Wednesday, February 2nd. Deutsche Bank Aktiengesellschaft lowered Quest Diagnostics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $190.00 to $129.00 in a research note on Friday, January 28th. Finally, Truist Financial dropped their price objective on Quest Diagnostics from $170.00 to $160.00 in a research note on Wednesday, January 19th. Seven equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $148.58.

In related news, SVP Michael E. Prevoznik sold 6,228 shares of the business’s stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $135.21, for a total value of $842,087.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Catherine T. Doherty sold 2,750 shares of the business’s stock in a transaction that occurred on Thursday, February 24th. The stock was sold at an average price of $126.26, for a total transaction of $347,215.00. The disclosure for this sale can be found here. Insiders own 1.45% of the company’s stock.

DGX stock traded up $2.07 during trading on Friday, reaching $140.00. 1,205,313 shares of the stock were exchanged, compared to its average volume of 1,312,219. The company has a current ratio of 1.56, a quick ratio of 1.44 and a debt-to-equity ratio of 0.62. The stock has a 50 day simple moving average of $136.41 and a 200-day simple moving average of $145.59. The company has a market capitalization of $16.49 billion, a P/E ratio of 9.00 and a beta of 1.12. Quest Diagnostics Incorporated has a twelve month low of $125.69 and a twelve month high of $174.16.

Quest Diagnostics (NYSE:DGXGet Rating) last released its quarterly earnings data on Thursday, February 3rd. The medical research company reported $3.33 earnings per share for the quarter, missing analysts’ consensus estimates of $3.35 by ($0.02). The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.66 billion. Quest Diagnostics had a net margin of 18.49% and a return on equity of 28.50%. The firm’s revenue for the quarter was down 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.48 earnings per share. Equities analysts predict that Quest Diagnostics Incorporated will post 9 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 20th. Stockholders of record on Wednesday, April 6th will be paid a $0.66 dividend. The ex-dividend date is Tuesday, April 5th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.89%. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.62. Quest Diagnostics’s payout ratio is 16.97%.

Quest Diagnostics Company Profile (Get Rating)

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXGet Rating).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.